Taken together, these data demonstrate that pharmacological inhibition of LSD1 had selective therapeutic effects on behavioral and cognitive impairments without influencing functions that were unaffected by transgenic expression of HERV-W ENV under basal conditions. The gene discussed is KDM1A; the disease is Cognitive impairment.